171 related articles for article (PubMed ID: 28865009)
1. Inverse relationship between Ki67 and survival in early luminal breast cancer: confirmation in a multivariate analysis.
Gallardo A; Garcia-Valdecasas B; Murata P; Teran R; Lopez L; Barnadas A; Lerma E
Breast Cancer Res Treat; 2018 Jan; 167(1):31-37. PubMed ID: 28865009
[TBL] [Abstract][Full Text] [Related]
2. Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index.
Kurozumi S; Matsumoto H; Hayashi Y; Tozuka K; Inoue K; Horiguchi J; Takeyoshi I; Oyama T; Kurosumi M
BMC Cancer; 2017 May; 17(1):354. PubMed ID: 28532429
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
[TBL] [Abstract][Full Text] [Related]
4. Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial.
Denkert C; Loibl S; Müller BM; Eidtmann H; Schmitt WD; Eiermann W; Gerber B; Tesch H; Hilfrich J; Huober J; Fehm T; Barinoff J; Jackisch C; Prinzler J; Rüdiger T; Erbstösser E; Blohmer JU; Budczies J; Mehta KM; von Minckwitz G
Ann Oncol; 2013 Nov; 24(11):2786-93. PubMed ID: 23970015
[TBL] [Abstract][Full Text] [Related]
5. Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer.
Milde-Langosch K; Karn T; Müller V; Witzel I; Rody A; Schmidt M; Wirtz RM
Breast Cancer Res Treat; 2013 Jan; 137(1):57-67. PubMed ID: 23135572
[TBL] [Abstract][Full Text] [Related]
6. Assessment of the predictive role of pretreatment Ki-67 and Ki-67 changes in breast cancer patients receiving neoadjuvant chemotherapy according to the molecular classification: a retrospective study of 1010 patients.
Chen R; Ye Y; Yang C; Peng Y; Zong B; Qu F; Tang Z; Wang Y; Su X; Li H; Yang G; Liu S
Breast Cancer Res Treat; 2018 Jul; 170(1):35-43. PubMed ID: 29480449
[TBL] [Abstract][Full Text] [Related]
7. High Ki67 predicts unfavourable outcomes in early breast cancer patients with a clinically clear axilla who do not receive axillary dissection or axillary radiotherapy.
Zurrida S; Bagnardi V; Curigliano G; Mastropasqua MG; Orecchia R; Disalvatore D; Greco M; Cataliotti L; D'Aiuto G; Talakhadze N; Goldhirsch A; Viale G
Eur J Cancer; 2013 Oct; 49(15):3083-92. PubMed ID: 23777741
[TBL] [Abstract][Full Text] [Related]
8. The prognostic value of Ki67 in systemically untreated patients with node-negative breast cancer.
Pathmanathan N; Balleine RL; Jayasinghe UW; Bilinski KL; Provan PJ; Byth K; Bilous AM; Salisbury EL; Boyages J
J Clin Pathol; 2014 Mar; 67(3):222-8. PubMed ID: 24403187
[TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of proliferation for resected early stage 'pure' invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validation.
Carbognin L; Sperduti I; Fabi A; Dieci MV; Kadrija D; Griguolo G; Pilotto S; Guarneri V; Zampiva I; Brunelli M; Orvieto E; Nortilli R; Fiorio E; Parolin V; Manfrin E; Caliò A; Nisticò C; Pellini F; Scarpa A; Pollini GP; Conte P; Tortora G; Bria E
Breast; 2017 Oct; 35():21-26. PubMed ID: 28628772
[TBL] [Abstract][Full Text] [Related]
10. Optimal Ki67 cut-off for luminal breast cancer prognostic evaluation: a large case series study with a long-term follow-up.
Bustreo S; Osella-Abate S; Cassoni P; Donadio M; Airoldi M; Pedani F; Papotti M; Sapino A; Castellano I
Breast Cancer Res Treat; 2016 Jun; 157(2):363-371. PubMed ID: 27155668
[TBL] [Abstract][Full Text] [Related]
11. Ki67 index in intrinsic breast cancer subtypes and its association with prognostic parameters.
Hashmi AA; Hashmi KA; Irfan M; Khan SM; Edhi MM; Ali JP; Hashmi SK; Asif H; Faridi N; Khan A
BMC Res Notes; 2019 Sep; 12(1):605. PubMed ID: 31547858
[TBL] [Abstract][Full Text] [Related]
12. Prognostic relevance of biological subtype overrides that of TNM staging in breast cancer: discordance between stage and biology.
Jung HA; Park YH; Kim M; Kim S; Chang WJ; Choi MK; Hong JY; Kim SW; Kil WH; Lee JE; Nam SJ; Ahn JS; Im YH
Tumour Biol; 2015 Feb; 36(2):1073-9. PubMed ID: 25326808
[TBL] [Abstract][Full Text] [Related]
13. The maximum standardized uptake value of metastatic site in 18 F-FDG PET/CT predicts molecular subtypes and survival in metastatic breast cancer: An Izmir Oncology Group study.
Cokmert S; Tanriverdi O; Karapolat I; Demir L; Bayoglu V; Can A; Akyol M; Yilmaz Y; Oktay Tarhan M
J BUON; 2016; 21(6):1410-1418. PubMed ID: 28039701
[TBL] [Abstract][Full Text] [Related]
14. Quantification of Ki67 Change as a Valid Prognostic Indicator of Luminal B Type Breast Cancer After Neoadjuvant Therapy.
Tan S; Fu X; Xu S; Qiu P; Lv Z; Xu Y; Zhang Q
Pathol Oncol Res; 2021; 27():1609972. PubMed ID: 34987312
[No Abstract] [Full Text] [Related]
15. Different prognosis of young breast cancer patients in their 20s and 30s depending on subtype: a nationwide study from the Korean Breast Cancer Society.
Ryu JM; Yu J; Kim SI; Kim KS; Moon HG; Choi JE; Jeong J; Do Byun K; Nam SJ; Lee JE; Lee SK; Kim SW
Breast Cancer Res Treat; 2017 Dec; 166(3):833-842. PubMed ID: 28831642
[TBL] [Abstract][Full Text] [Related]
16. New insights into the prognostic value of Ki-67 labeling index in patients with triple-negative breast cancer.
Hao S; He ZX; Yu KD; Yang WT; Shao ZM
Oncotarget; 2016 Apr; 7(17):24824-31. PubMed ID: 27050075
[TBL] [Abstract][Full Text] [Related]
17. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
18. Ki67 Changes Identify Worse Outcomes in Residual Breast Cancer Tumors After Neoadjuvant Chemotherapy.
Cabrera-Galeana P; Muñoz-Montaño W; Lara-Medina F; Alvarado-Miranda A; Pérez-Sánchez V; Villarreal-Garza C; Quintero RM; Porras-Reyes F; Bargallo-Rocha E; Del Carmen I; Mohar A; Arrieta O
Oncologist; 2018 Jun; 23(6):670-678. PubMed ID: 29490940
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups.
Abubakar M; Orr N; Daley F; Coulson P; Ali HR; Blows F; Benitez J; Milne R; Brenner H; Stegmaier C; Mannermaa A; Chang-Claude J; Rudolph A; Sinn P; Couch FJ; Devilee P; Tollenaar RA; Seynaeve C; Figueroa J; Sherman ME; Lissowska J; Hewitt S; Eccles D; Hooning MJ; Hollestelle A; Martens JW; van Deurzen CH; ; Bolla MK; Wang Q; Jones M; Schoemaker M; Wesseling J; van Leeuwen FE; Van 't Veer L; Easton D; Swerdlow AJ; Dowsett M; Pharoah PD; Schmidt MK; Garcia-Closas M
Breast Cancer Res; 2016 Oct; 18(1):104. PubMed ID: 27756439
[TBL] [Abstract][Full Text] [Related]
20. Bcl2 and Ki67 refine prognostication in luminal breast cancers.
Chen LY; Tsang JY; Ni YB; Chan SK; Chan KF; Zhang S; Tse GM
Breast Cancer Res Treat; 2015 Feb; 149(3):631-43. PubMed ID: 25648135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
